Snowden Capital Advisors’s Alnylam Pharmaceuticals ALNY Stock Holding History

Snowden Capital Advisors’s Portfolio ALNY Stock Details ALNY Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$263K	Sell	875 -41	-4%	-$12.4K	0.01%	1145
2026 Q1	$303K	Buy	916 +82	+10%	+$27.9K	0.01%	1026
2025 Q4	$332K	Sell	834 -33	-4%	-$14.6K	0.01%	1015
2025 Q3	$395K	Sell	867 -269	-24%	-$110K	0.01%	894
2025 Q2	$370K	Buy	1,136 +307	+37%	+$84.9K	0.01%	915
2025 Q1	$224K	Buy	+829	New	+$213K	0.01%	1113
2022 Q1	–	Sell	-22	Closed	-$3K	–	1063
2021 Q4	$3K	Buy	+22	New	+$4.09K	﹤0.01%	1781

Other funds holding ALNY

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Capital Research Global Investors Los Angeles, California $717B AUM 35.42% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return

Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Snowden Capital Advisors's ALNY Position: Q2 2026 in Review

Snowden Capital Advisors reduced its Alnylam Pharmaceuticals (ALNY) stake by 4.5% in Q2 2026, selling an estimated $12.4K and leaving 875 shares worth $263K. The position accounts for 0.01% of the portfolio, ranked #1145.

Snowden Capital Advisors first reported a position in ALNY in Q4 2021 and has held it in 7 quarters since. The position peaked at $395K in Q3 2025. 788 funds tracked by Wall St. Rank hold ALNY as of Q2 2026.

Snowden Capital Advisors held 875 shares of Alnylam Pharmaceuticals worth $263K as of Q2 2026.
Snowden Capital Advisors sold 41 Alnylam Pharmaceuticals shares in Q2 2026, an estimated $12.4K.
Alnylam Pharmaceuticals made up 0.01% of Snowden Capital Advisors's portfolio in Q2 2026, its #1145 holding.
Snowden Capital Advisors first reported a position in Alnylam Pharmaceuticals in Q4 2021 and has held it in 7 quarters since.
Snowden Capital Advisors's Alnylam Pharmaceuticals position peaked at $395K in Q3 2025.
788 funds tracked by Wall St. Rank held Alnylam Pharmaceuticals as of Q2 2026.

Based on Snowden Capital Advisors's 13F filing for Q2 2026, filed 13 Aug 2026.